Khodashahi Rozita, Jajroudi Mahdieh, Ferns Gordon A, Aliakbarian Mohsen, Arjmand Mohammad-Hassan
Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gastroenterol Hepatol Bed Bench. 2025;18(1):21-31. doi: 10.22037/ghfbb.v18i1.2965.
Thus, this meta-analysis was performed to assess the prognostic value of serum uric acid in patients with gastrointestinal cancers (GI).
There is growing evidence that high serum uric acid may be used as a potential prognostic marker in gastrointestinal malignancies. However, there are inconsistencies in the reported findings.
Related studies were identified by searching the following databases: PubMed, Web of Science, Cochrane Library, and Scopus, independently up until 30 October 2023. Relevant analyses were carried out to deal with heterogeneity in the data. According to the inclusion criteria, we used English original papers reporting prognostic value of serum/plasma uric acid to determine hazard ratio (HR) and 95% confidence interval (CI) in patients with GI cancers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to ascertain the association of uric acid levels with gastrointestinal cancer (GI) risk. The inconsistency index (I2) was used to calculate the level of heterogeneity among the selected studies. The quality of each study was evaluated by Newcastle-OTTAWA Scales (NOS).
A total of 9 papers with 95.285 patients were included in this meta-analysis. The findings indicated a significant association between serum uric acid and poor prognosis in patients with gastrointestinal cancers (HR=1.477, 95% CI 1.165-1.873, P= 0.001). Further, in Subgroup analysis we found that patients would have poor survival rate among different cut-offs of uric acid, ≥ 5mg/dl, HR= 1.403, 95% CI=1.150-1.711, P=0.001 vs cut-off <5mg/dl, HR=1.54, 95% CI=1.140-2.063, P=0.005.
Serum uric acid level is significantly linked to survival outcomes in patients with gastrointestinal cancers. Serum uric acid levels may be an effective prognostic marker associated with clinical outcomes in patients with gastrointestinal cancers. Given the small number of studies included in this meta-analysis and high heterogeneity, we suggest that a more comprehensive study is required to achieve more robust results.
因此,本荟萃分析旨在评估血清尿酸在胃肠道癌(GI)患者中的预后价值。
越来越多的证据表明,高血清尿酸可能作为胃肠道恶性肿瘤的潜在预后标志物。然而,报告的研究结果存在不一致性。
通过检索以下数据库独立识别相关研究:截至2023年10月30日的PubMed、Web of Science、Cochrane图书馆和Scopus。进行了相关分析以处理数据中的异质性。根据纳入标准,我们使用报告血清/血浆尿酸预后价值的英文原始论文来确定胃肠道癌患者的风险比(HR)和95%置信区间(CI)。合并风险比(HRs)及其95%置信区间(CIs)用于确定尿酸水平与胃肠道癌(GI)风险之间的关联。不一致指数(I2)用于计算所选研究之间的异质性水平。每项研究的质量通过纽卡斯尔-渥太华量表(NOS)进行评估。
本荟萃分析共纳入9篇论文,涉及95285名患者。研究结果表明,血清尿酸与胃肠道癌患者的预后不良之间存在显著关联(HR=1.477,95%CI 1.165-1.873,P=0.001)。此外,在亚组分析中,我们发现尿酸不同临界值时患者的生存率存在差异,尿酸≥5mg/dl时,HR=1.403,95%CI=1.150-1.711,P=0.001;而尿酸临界值<5mg/dl时,HR=1.54,95%CI=1.140-2.063,P=0.005。
血清尿酸水平与胃肠道癌患者的生存结果显著相关。血清尿酸水平可能是与胃肠道癌患者临床结果相关的有效预后标志物。鉴于本荟萃分析纳入的研究数量较少且异质性较高,我们建议需要进行更全面的研究以获得更可靠的结果。